Navigation Links
American Oriental Bioengineering Inc. Announces Suspension of Trading in its Common Stock and the Initiation of Delisting Proceedings by NYSE
Date:5/31/2012

NEWARK, N. J., May 31, 2012 /PRNewswire-Asia-FirstCall/ -- American Oriental Bioengineering, Inc. (NYSE: AOB) (the "Company"), today announced that it received written notification on May 25, 2012, from the NYSE Regulation, Inc. staff, on behalf of the New York Stock Exchange LLC ("NYSE"), that the staff had determined to immediately suspend trading in the common stock of the Company and file a delisting application with the United States Securities and Exchange Commission (the "SEC") pursuant to Section 804.00 of the Listed Company Manual. The staff stated in its notice that it had determined that the Company no longer meets the standard for continued listing on the NYSE and that it is necessary and appropriate for the protection of investors to immediately suspend trading in its common stock and initiate delisting proceedings. Trading in the Company's common stock on the NYSE had been halted since March 16, 2012.

As a result of the above actions, on Tuesday, May 29, 2012, the Company's common stock commenced quotation on the OTC Markets under the ticker symbol "AOBI."

About American Oriental Bioengineering, Inc.

American Oriental Bioengineering, Inc. is a pharmaceutical company dedicated to improving health through the development, manufacture and commercialization of a broad range of prescription and over the counter products. 

Safe Harbor Statement

Statements made in this press release are forward-looking and are made pursuant to the safe harbor provisions of the Securities Litigation Reform Act of 1995. Such statements involve risks and uncertainties that may cause actual results to differ materially from those set forth in these statements. The economic, competitive, governmental, technological and other factors identified in the Company's filings with the Securities and Exchange Commission, may cause actual results or events to differ materially from those described in the forward looking statements in this press release. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether because of new information, future events, or otherwise.

Contact:

Kewa Luo
646-367-1765


'/>"/>
SOURCE American Oriental Bioengineering, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Attack on the Website of the American Pharmacists Association
2. American Society of Hematology Statement on House Passage of Prescription Drug User Fee Act (PDUFA)
3. COPD Tops Asthma as the Focus Indication for Next Generation Respiratory Therapies at the 2012 American Thoracic Society Conference
4. Novocure™ to Present NovoTTF™ Therapy Data at the 2012 Annual Scientific Meeting of the American Society of Clinical Oncology
5. EQUICARE CS Cancer Survivorship Case Management Software Listed as a "Best Practices" Resource by the American College of Surgeons Commission on Cancer (COC)
6. Agendia Announces Nine Studies in Breast and Colon Cancer for Presentation at 2012 Annual Meeting of the American Society of Clinical Oncology (ASCO)
7. American Society of Hematology Statement on Senate Passage of Prescription Drug User Fee Act (PDUFA)
8. Lilly Diabetes Presents Phase II Blood Pressure and Heart Rate Data on Investigational GLP-1 Analog Candidate, Dulaglutide, in Patients with Type 2 Diabetes at the 27th American Society of Hypertension Scientific Meeting
9. Percutaneous Tibial Nerve Stimulation Included in the American Urological Associations Overactive Bladder Clinical Treatment Guidelines
10. Purdue Pharma L.P. To Present Analysis Of Butrans® (buprenorphine) Transdermal System CIII Clinical Data At American Pain Society Annual Meeting
11. Pharmacyclics Announces Oral Presentations and Clinical Update of Ibrutinib (PCI-32765) at the 2012 Annual Meeting of the American Society of Clinical Oncology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/26/2020)... , ... August 26, 2020 , ... As the U.S. ... the daily routine for preventing the Coronavirus. Wear a mask, keep your distance, wash ... advocate Dr. Denis Burkitt said it best in 1977, “How much better it is ...
(Date:8/26/2020)... ... 26, 2020 , ... Hero Life Sciences announced today that it ... ply surgical disposable face masks and N95 respirators in its manufacturing plant located in ... that most Americans are facing in trying to find quality disposable face masks during ...
(Date:8/26/2020)... ... August 26, 2020 , ... NucleusHealth, LLC, ... E. Hooton as President and Chief Executive Officer effective immediately. Dr. Vishal Verma, ... company’s Board of Managers. , Mr. Hooton, a seasoned business executive, joined ...
Breaking Medicine Technology:
(Date:9/1/2020)... COSTA MESA, Calif. (PRWEB) , ... September 01, 2020 , ... ... on the “safe side”, the Cohn Health Institute has taken this time ... decades. In celebration of its 30th Anniversary, the Cohn Health Institute will be relaunching ...
(Date:8/31/2020)... ... August 31, 2020 , ... The Lymphoma Research Foundation ... lymphoma research and serving the lymphoma community through a comprehensive series of education ... Blood Cancer Awareness Month (BCAM) and its international Light it Red for ...
(Date:8/31/2020)... ... 2020 , ... Want to get moving, break up your routine, and make ... thrilled to launch its fourth annual STEPtember campaign in the United States to raise ... wherever they are at this moment — encouraging people to move in the ways ...
(Date:8/31/2020)... ... August 31, 2020 , ... ... services to dental groups in the United States, today announced the grand opening ... Beaumont, CA. , Patients will enjoy convenient hours, a comfortable office, and ...
(Date:8/31/2020)... ... August 31, 2020 , ... In an effort to give back to ... 10 percent of each hotel room booked with a special new rate code to ... Indiana (RMHC-CNI) , effective immediately. Donations will be applied to any room type, ...
Breaking Medicine News(10 mins):